|Mr. Douglas Arthur Doerfler||Co-Founder, Pres, CEO & Exec. Director||644.38k||N/A||1956|
|Mr. Ronald Evan Holtz||CFO, Company Sec. & Director||414.48k||N/A||1958|
|Mr. Maher Masoud||VP of Legal||N/A||N/A||N/A|
|Mr. Thomas Michael Ross||Exec. VP of Global Sales||N/A||N/A||1961|
|Mr. Markus J. Hunkeler||VP of Marketing||N/A||N/A||N/A|
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers, as well as transfection insourcing services. In addition, it develops CARMA, a messenger ribonucleic acid autologous platform for immune-oncology that enables manufacture and controllable delivery of next-generation chimeric antigen receptor engineered T/NK-cell therapies for a range of cancer indications, including solid tumors. The company licenses and sells its instruments and technology; and sells its disposable processing assemblies to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. It has a cooperative research and development agreement with the National Institutes of Health's and National Institute of Allergy and Infectious Diseases to develop treatments for X-linked chronic granulomatous disease using gene correction leveraging CRISPR/Cas9; and a research agreement with Kite Pharma, Inc. to enable non-viral cell engineering. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
MaxCyte, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.